Despite that EZH2 is commonly overexpressed in high risk MDS and AML, the observation that loss of function mutations affect patients with MDS/MPN, myelofibrosis, and various MDS entities highlights the fact that EZH2 can function as tumor suppressor and oncogene depending on the cellular context (125). Here, EZH2 is linked to myelodysplastic syndrome.